Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Lederer

Showing results (151-160 of 219) with videos related to

Pageof 22
Sort By:
Thorax|January 29, 2017
Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA studyAnna J Podolanczuk, Ganesh Raghu, Michael Y Tsai, et al.
American Journal of Respiratory and Critical Care Medicine|August 8, 2009
Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunctionJason D Christie, Chirag V Shah, Steven M Kawut, et al.
BMJ Open Respiratory Research|February 3, 2016
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trialsLisa Lancaster, Carlo Albera, Williamson Z Bradford, et al.
The New England Journal of Medicine|May 20, 2014
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosisTalmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, et al.
ERJ Open Research|September 25, 2024
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPDKlaus F Rabe, Fernando J Martinez, Surya P Bhatt, et al.
The European Respiratory Journal|December 10, 2015
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsPaul W Noble, Carlo Albera, Williamson Z Bradford, et al.
Chest|November 5, 2017
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary FibrosisIvan O Rosas, Hilary J Goldberg, Harold R Collard, et al.
The Journal of Thoracic and Cardiovascular Surgery|May 30, 2007
Lung-volume reduction surgery for pulmonary emphysema: Improvement in body mass index, airflow obstruction, dyspnea, and exercise capacity index after 1 yearDavid J Lederer, Byron M Thomashow, Mark E Ginsburg, et al.
Thorax|October 28, 2017
Associations between emphysema-like lung on CT and incident airflow limitation: a general population-based cohort studyElizabeth C Oelsner, Benjamin M Smith, Eric A Hoffman, et al.
Science Immunology|March 10, 2019
Generation and persistence of human tissue-resident memory T cells in lung transplantationMark E Snyder, Michael O Finlayson, Thomas J Connors, et al.
Pageof 22

Showing results (151-160 of 219) with videos related to

Sort By:
Pageof 22
Thorax|January 29, 2017
Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA studyAnna J Podolanczuk, Ganesh Raghu, Michael Y Tsai, et al.
American Journal of Respiratory and Critical Care Medicine|August 8, 2009
Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunctionJason D Christie, Chirag V Shah, Steven M Kawut, et al.
BMJ Open Respiratory Research|February 3, 2016
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trialsLisa Lancaster, Carlo Albera, Williamson Z Bradford, et al.
The New England Journal of Medicine|May 20, 2014
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosisTalmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, et al.
ERJ Open Research|September 25, 2024
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPDKlaus F Rabe, Fernando J Martinez, Surya P Bhatt, et al.
The European Respiratory Journal|December 10, 2015
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsPaul W Noble, Carlo Albera, Williamson Z Bradford, et al.
Chest|November 5, 2017
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary FibrosisIvan O Rosas, Hilary J Goldberg, Harold R Collard, et al.
The Journal of Thoracic and Cardiovascular Surgery|May 30, 2007
Lung-volume reduction surgery for pulmonary emphysema: Improvement in body mass index, airflow obstruction, dyspnea, and exercise capacity index after 1 yearDavid J Lederer, Byron M Thomashow, Mark E Ginsburg, et al.
Thorax|October 28, 2017
Associations between emphysema-like lung on CT and incident airflow limitation: a general population-based cohort studyElizabeth C Oelsner, Benjamin M Smith, Eric A Hoffman, et al.
Science Immunology|March 10, 2019
Generation and persistence of human tissue-resident memory T cells in lung transplantationMark E Snyder, Michael O Finlayson, Thomas J Connors, et al.
Pageof 22